Antiphospholipid syndrome (APS) is an autoimmune disorder that presents with hypercoagulability and results in a lab artifact of prolonged PTT. The most severe form is catastrophic antiphospholipid antibody syndrome (CAPS), which manifests as rapidly progressing thromboses in multiple organ systems leading to multi-organ ischemia. The mainstay management CAPS is anticoagulation and systemic corticosteroids. Antifibrinolytic agents have previously been thought to be relatively contraindicated in CAPS due to the pro-thrombotic nature of the disease; the complex coagulation profile of CAPS can make it difficult to assess the risks and benefits of antifibrinolytic therapy. Also, should a patient with CAPS require cardiopulmonary bypass (CPB) for surgery, it poses a unique challenge in providing appropriate anticoagulation in the setting of prolonged ACT. We present a case of a 32-year-old postpartum female with CAPS requiring heart transplant who safely received intraoperative antifibrinolytic therapy and was successfully anticoagulated during CPB after perioperative plasmapheresis.
Duarte-GarcíaAPhamMCrowsonC, et al.The epidemiology of antiphospholipid syndrome: a population-based study [published correction appears in arthritis rheumatol. 2020 apr;72(4):597]. Arthritis Rheumatol. 2019;71(9):1545-1552. doi:10.1002/art.40901.
2.
MiyakisSLockshinMAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.
3.
SchorerAWickhamNWatsonK. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol. 1989;71(3):399-407. doi:10.1111/j.1365-2141.1989.tb04298.x.
4.
TsakirisDMarbetGMakrisP, et al.Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemostasis. 1989;61:175-177.
5.
EscolarGFontJReverterJ, et al.Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation: studies in a perfusion system. Arterioscler Thromb. 1992;12(2):196-200. doi:10.1161/01.atv.12.2.196.
6.
GarciaDErkanD. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi:10.1056/NEJMra1705454.
7.
BucciarelliSEspinosaGCerveraR. European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-2576. doi:10.1002/art.22018.
8.
SevimEZisaDAndradeD, et al.Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository. Arthritis Care Res. 2022;74(2):324-335. doi:10.1002/acr.24468.
9.
YunZDuanLLiuX, et al.An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol. 2023;14:1145145. doi:10.3389/fimmu.2023.1145145.
10.
MassoudyPCetinSThielmannM, et al.Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder?Eur J Cardio Thorac Surg. 2005;28:133-137. doi:10.1016/j.ejcts.2004.12.062.
11.
ChaturvediSBraunsteinEYuanX, et al.Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239-251. doi:10.1182/blood.2019003863.
12.
CerveraRBucciarelliSPlasinM, et al.Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the ‘‘CAPS Registry. J Autoimmun. 2009;32:240-245.
EspinosaGBermanHCerveraR. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev. 2011;10:664-668.
15.
OkamotoSHijikata-OkunomiyaAWanakaK, et al.Enzyme-controlling medicines: introduction. Semin Thromb Hemost. 1997;23(6):493-501. doi:10.1055/s-2007-996127.
16.
BakerSKStricklandS. A critical role for plasminogen in inflammation. J Exp Med. 2020;217(4):e20191865. doi:10.1084/jem.2019186.
17.
FröjdVJeppssonA. Reexploration for bleeding and its association with mortality after cardiac surgery. Ann Thorac Surg. 2016;102(1):109-117. doi:10.1016/j.athoracsur.2016.01.006.
18.
BrownJKilicAAranda-MichelE, et al.Long-term outcomes of reoperation for bleeding after cardiac surgery. Semin Thorac Cardiovasc Surg. 2021;33(3):764-773. doi:10.1053/j.semtcvs.2020.11.013.
19.
MurphyGReevesBRogersC, et al.Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544-2552. doi:10.1161/CIRCULATIONAHA.107.698977.
20.
GuoJGaoXMaY, et al.Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. BMC Anesthesiol. 2019;19(1):129. doi:10.1186/s12871-019-0772-0.
21.
JimenezJIribarrenJLorenteL, et al.Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007;11(6):R117. doi:10.1186/cc6173.
22.
MylesPSmithJForbesA, et al.Tranexamic acid in patients undergoing coronary-artery surgery [published correction appears in N engl J med. 2018 feb 22;378(8):782]. N Engl J Med. 2017;376(2):136-148. doi:10.1056/NEJMoa160642.
23.
DunnCJGoaKL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-1032. doi:10.2165/00003495-199957060-00017.
24.
HoKIsmailH. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003;31(5):529-537. doi:10.1177/0310057X0303100507.
25.
KerKEdwardsPPerelP, et al.Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. doi:10.1136/bmj.e3054.
26.
FujikawaT. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022;387(9):858. doi:10.1056/NEJMc2208614.
27.
WhitingDGilletteBDuncanC, et al.Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014;472(1):66-72. doi:10.1007/s11999-013-3134-0.
28.
EastCClementsFMathewJ, et al.Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg. 2000;90(5):1098-1101. doi:10.1097/00000539-200005000-00017.
29.
RandJWuXAndreeH, et al.Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood. 1998;92(5):1652-1660.
30.
SubramaniamKKumarAHernandezS, et al.Effect of blood product transfusion on perioperative outcomes after heart transplantation. J Cardiothorac Vasc Anesth. 2021;35(4):1067-1072. doi:10.1053/j.jvca.2020.10.024.
31.
Rodríguez-PintóILozanoMCidJ, et al.Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med. 2019;48(11 Pt 2):347-353. doi:10.1016/j.lpm.2019.10.003.
32.
SheikhFLechowiczASetlurR, et al.Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1997;11(6):764-766. doi:10.1016/s1053-0770(97)90173-7.
33.
DucartACollardEOsselaerJ, et al.Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothorac Vasc Anesth. 1997;11(7):878-879. doi:10.1016/s1053-0770(97)90125-7.
34.
TaeuberIWeibelSHerrmannE, et al.Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression [published online ahead of print, 2021 apr 14]. JAMA Surg. 2021;156(6):e210884. doi:10.1001/jamasurg.2021.0884.
35.
WendteJVossGVan OverscheldeB. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. Am J Health Syst Pharm. 2016;73(8):563-567. doi:10.2146/ajhp150360.
36.
Hutt CentenoEMilitelloMGomesM. Anti-Xa assays: what is their role today in antithrombotic therapy?Cleve Clin J Med. 2019;86(6):417-425. doi:10.3949/ccjm.86a.18029.
37.
FaustAKanyerDWittkowskyA. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm. 2016;73(24):2037-2041. doi:10.2146/ajhp150596.
